Management of Benign Axillary Lymphadenopathy

Initial Assessment and Follow-Up

The National Comprehensive Cancer Network recommends benign biopsy results be followed up with appropriate monitoring due to the possibility of sampling error, especially with larger nodes 1

The National Comprehensive Cancer Network recommends ultrasound monitoring every 6 months for 1-2 years to ensure stability 1
This approach allows for detection of any changes in size, morphology, or cortical features that might indicate need for re-biopsy, as suggested by clinical guidelines 2

If there are changes in lymph node characteristics during follow-up, consider diagnostic mammography if not already performed, as recommended by the National Comprehensive Cancer Network 1
Breast MRI may be considered if mammogram is negative but clinical suspicion remains high, according to the National Comprehensive Cancer Network and other clinical guidelines 1, 2
PET/CT may be considered if there is concern for lymphoma or other non-breast malignancy, as suggested by the American College of Radiology and other clinical guidelines 3, 2

Inflammatory processes, such as reactive hyperplasia, and dermatopathic lymphadenopathy from skin conditions are potential causes of benign axillary lymphadenopathy, as noted in clinical guidelines 2

Benign biopsy results should be correlated with clinical findings; persistent symptoms or changes in the lymph node should prompt reconsideration of management, as recommended by the National Comprehensive Cancer Network and other clinical guidelines 1, 2